ArticleBMC veterinary research2026
Development of a novel nanobody-based competitive ELISA for rapid detection of antibodies against Senecavirus A.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSenecavirus A (SVA) causes considerable economic losses in the swine industry, particularly among piglets. However, effective serological diagnostic assays for SVA are still lacking. A testing platform based on nanobody-horseradish peroxidase (Nb-HRP) fusion protein-based competitive ELISA (cELISA) for the detection of antibodies against various animal viruses is available. In this study, a rapid and reliable cELISA was established using this platform for specific detection of antibodies against SVA.
resultsTwo anti-SVA nanobodies were selected from an immunized Bactrian camel using phage display technology. The Nb84-HRP fusion protein was expressed and used as a probe during the process. The assay exhibited a cut-off value of 19.4% and showed no cross-reactivity with antibodies against other swine viruses, demonstrating high specificity. The intra- and inter-assay coefficients of variation ranged from 1.44% to 3.27% and 1.36% to 8.71%, respectively. Evaluation using clinical swine serum samples showed a higher coincidence rate between the cELISA and Western blot (99%, kappa value = 0.97) than that between the cELISA and a commercial ELISA kit (84%, kappa value = 0.35).
conclusionsThese results indicate that the cELISA developed in this study is a rapid, cost-effective, and reliable method for serological detection and surveillance of SVA infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.